Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

Gap Junctions

Gap Junctions

Multicellular organisms employ a variety of ways for cells to communicate with each other. Gap junctions are specialized proteins that form pores between neighboring cells in animals, connecting the cytoplasm between the two, and allowing for the exchange of molecules and ions. They are found in a wide range of invertebrate and vertebrate species, mediate numerous functions including cell differentiation and development, and are associated with numerous human diseases, including cardiac and...

Gap Junctions

Gap Junctions

The cytoplasm of adjacent animal cells can exchange small molecules, ions, and secondary messengers via the communication channels which form the gap junctions. These junctions comprise a few hundred to thousands of molecular channels, each made of two halves, called the connexon hemichannel. A connexon is a hexamer of six transmembrane connexin proteins, which assemble radially, thus forming a pore or channel in the center. One connexon hemichannel docks with a corresponding connexon on the...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pannexin1-dependent and -independent protection by novel peptidomimetics against cardiac ischemia/reperfusion injury.

Scientific reports·2026

Same author

Towards replacement of animal experimentation in scientific research and regulatory testing: launch of <i>NAM Journal</i>.

NAM journal·2026

Same author

The Alarming Consequences of Workforce Reductions at the FDA, EPA, NIH and CDC in the United States.

NAM journal·2026

Same author

Transitional initiatives for advancing the phasing out of the use of animals for drug and chemical safety testing: The IHI VICT3R project for reducing the use of animals by implementing virtual control groups.

NAM journal·2026

Same author

Transcriptomic responses to repeated exposure of human C3A liver spheroids to polystyrene nanoplastics.

Archives of toxicology·2026

Same author

A combined in silico and in vitro new approach methodology for early detection of liver steatogenic chemicals.

Chemico-biological interactions·2026

Search research articles

Related Experiment Video

Updated: May 22, 2026

Gap Junctional Intercellular Communication: A Functional Biomarker to Assess Adverse Effects of Toxicants and Toxins, and Health Benefits of Natural Products

Gap Junctional Intercellular Communication: A Functional Biomarker to Assess Adverse Effects of Toxicants and Toxins, and Health Benefits of Natural Products

Published on: December 25, 2016

Gap junctions and non-neoplastic liver disease.

Mathieu Vinken¹

¹Department of Toxicology, Center for Pharmaceutical Research, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium. mvinken@vub.ac.be

Journal of Hepatology

|May 22, 2012

Summary

Gap junctions maintain liver health and are altered in liver disease. This review details changes in connexins, the gap junction proteins, and their potential as biomarkers and therapeutic targets in various liver conditions.

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

An Iodide-Yellow Fluorescent Protein-Gap Junction-Intercellular Communication Assay

An Iodide-Yellow Fluorescent Protein-Gap Junction-Intercellular Communication Assay

Published on: February 1, 2019

Related Experiment Videos

Last Updated: May 22, 2026

Gap Junctional Intercellular Communication: A Functional Biomarker to Assess Adverse Effects of Toxicants and Toxins, and Health Benefits of Natural Products

Gap Junctional Intercellular Communication: A Functional Biomarker to Assess Adverse Effects of Toxicants and Toxins, and Health Benefits of Natural Products

Published on: December 25, 2016

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

An Iodide-Yellow Fluorescent Protein-Gap Junction-Intercellular Communication Assay

An Iodide-Yellow Fluorescent Protein-Gap Junction-Intercellular Communication Assay

Published on: February 1, 2019

Area of Science:

Hepatology
Cellular Biology
Molecular Medicine

Background:

Gap junctions are crucial for maintaining liver homeostasis.
Their role in hepatocarcinogenesis is well-established.
Less is known about gap junction alterations in other liver diseases.

Purpose of the Study:

To comprehensively review changes in gap junction expression, localization, and function in diverse liver pathologies.
To explore the potential of connexins as biomarkers and therapeutic targets in liver disease.

Main Methods:

Literature review focusing on connexins and liver diseases.
Analysis of studies examining gap junction alterations in hepatitis, fibrosis, cirrhosis, cholestasis, and ischemia-reperfusion injury.

Main Results:

Connexins, the molecular components of gap junctions, undergo significant changes in expression and localization during liver disease.
These alterations impact hepatic homeostasis and disease progression.
Connexins show promise as diagnostic biomarkers and therapeutic targets.

Conclusions:

Gap junction dysfunction is a common feature across various liver pathologies.
Targeting connexins offers a potential therapeutic strategy for liver diseases.
Further research is warranted to fully elucidate the role of connexins in liver disease management.